ClinicalTrials.gg
CompletedNCT02516046Updated Sep 7, 2020Results posted

18F-AV-1451 Autopsy Study

A Phase 3 interventional study of Flortaucipir F18 and PET Scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 31 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-09-07.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
8th of 22
156 · median 70
Started
2015
with 3 others
Phase 3
3 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 8th largest by enrollment, is one of 4 that started in 2015, is one of 3 in phase 3, and was the 11th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a projected of ≤ 6 months
  • Can tolerate a 20 minute PET scan
  • Give or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die

Exclusion criteria

Exclusion Criteria:

  • Aggressively being treated with life sustaining measures
  • Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment
  • infectious disease
  • Currently receiving any medications except with permission from the study sponsor
  • Participated in an experimental study with an amyloid or tau targeting agent
  • Suspected encephalopathy due to alcoholism or end-stage liver disease
  • Females of
  • History of risk factors for Torsades de Pointes or are currently taking medication known to cause
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Flortaucipir PET Scan

    Drug: Flortaucipir F18 · Procedure: PET Scan

Interventions

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: [F-18]T807, 18F-AV-1451, LY3191748

  • ProcedurePET Scan

    positron emission tomography (PET) scan

06

What researchers measure

Primary outcomes

  1. Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score)

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (Braak Stage 0; no NFTs in the brain) to B3 (Braak Stage V/VI; widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

    Time frame: at autopsy within 9 months of baseline scan

  2. Primary Outcome 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to high levels of Alzheimer's disease neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain (Hyman et al., Alzheimers Dement. 2012 Jan;8(1):1-13). The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

    Time frame: at autopsy within 9 months of baseline scan

Secondary outcomes

  1. Flortaucipir Diagnostic Performance (NFT Score)

    Sensitivity and specificity of majority interpretation of AD pattern tau PET scan corresponding to NFT Score of B3. The 95% confidence intervals (CI) provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.

    Time frame: at autopsy within 9 months of baseline scan

  2. Flortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis)

    Sensitivity and specificity of majority interpretation of of AD pattern tau PET scan corresponding to NIA-AA autopsy diagnosis. The 95% CIs provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.

    Time frame: at autopsy within 9 months of baseline scan

  3. Inter-Reader Agreement

    Fleiss' Kappa statistics were used to assess inter-reader agreement for the diagnostic decisions associated with primary outcome 1. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Results are reported as overall agreement, calculated as proportion of scans where reader pairs agreed, divided by the total number of scans read by each reader pair.

    Time frame: baseline scan

Other outcomes

  1. Diagnostic Performance of Individual Readers (NFT Score B2-B3 as Truth Positive)

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. For this analysis, B scores of B2-B3 were considered truth positive, and B scores of B0-B1 were considered truth negative.

    Time frame: at autopsy within 9 months of baseline scan

07

Results

Posted Sep 7, 2020

Participant flow

Enrollment occurred between October 2015 and June 2018. Enrolled end-of-life subjects (life expectancy less than 6 months) at hospice centers in the US and Australia consented to a flortaucipir PET scan and to brain donation at autopsy.

Participant flow — Overall Study
MilestoneAll Enrolled Cohort
Started156
Died while on study73
Valid autopsy results and pet scan67
Completed64
Not completed92

Outcome measures

PrimaryPrimary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score)

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (Braak Stage 0; no NFTs in the brain) to B3 (Braak Stage V/VI; widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

Time frame:
at autopsy within 9 months of baseline scan
Reported as:
Number · percentage of cases correctly identified
Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs Autopsy NFT Score B3Specificity of Flortaucipir vs Autopsy NFT Score <B3
Reader 197.4 (86.8 to 99.5)68.0 (48.4 to 82.8)
Reader 292.3 (79.7 to 97.3)92.0 (75.0 to 97.8)
Reader 392.3 (79.7 to 97.3)88.0 (70.0 to 95.8)
Reader 492.3 (79.7 to 97.3)76.0 (56.6 to 88.5)
Reader 5100 (91.0 to 100.0)52.0 (33.5 to 70.0)
PrimaryPrimary Outcome 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to high levels of Alzheimer's disease neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain (Hyman et al., Alzheimers Dement. 2012 Jan;8(1):1-13). The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

Time frame:
at autopsy within 9 months of baseline scan
Reported as:
Number · percentage of cases correctly identified
Primary Outcome 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs NIA-AA Autopsy DiagnosisSpecificity of Flortaucipir vs NIA-AA Autopsy Diagnosis
Reader 197.5 (87.1 to 99.6)65.4 (46.2 to 80.6)
Reader 295.0 (83.5 to 98.6)92.3 (75.9 to 97.9)
Reader 395.0 (83.5 to 98.6)88.5 (71.0 to 96.0)
Reader 495.0 (83.5 to 98.6)76.9 (57.9 to 89.0)
Reader 5100 (91.2 to 100.0)50.0 (32.1 to 67.9)
SecondaryFlortaucipir Diagnostic Performance (NFT Score)

Sensitivity and specificity of majority interpretation of AD pattern tau PET scan corresponding to NFT Score of B3. The 95% confidence intervals (CI) provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.

Time frame:
at autopsy within 9 months of baseline scan
Reported as:
Number · percentage of cases correctly identified
Flortaucipir Diagnostic Performance (NFT Score)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs Autopsy NFT Score B3Specificity of Flortaucipir vs Autopsy NFT Score <B3
Flortaucipir Diagnostic Performance (NFT Score)92.3 (79.7 to 97.3)80.0 (60.9 to 91.1)
SecondaryFlortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis)

Sensitivity and specificity of majority interpretation of of AD pattern tau PET scan corresponding to NIA-AA autopsy diagnosis. The 95% CIs provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.

Time frame:
at autopsy within 9 months of baseline scan
Reported as:
Number · percentage of cases correctly identified
Flortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis)
percentage of cases correctly identifiedSensitivity Majority Read NIA-AA Autopsy DiagnosisSpecificity Majority Read NIA-AA Autopsy Diagnosis
Flortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis)94.7 (82.7 to 98.5)80.8 (62.1 to 91.5)
SecondaryInter-Reader Agreement

Fleiss' Kappa statistics were used to assess inter-reader agreement for the diagnostic decisions associated with primary outcome 1. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Results are reported as overall agreement, calculated as proportion of scans where reader pairs agreed, divided by the total number of scans read by each reader pair.

Time frame:
baseline scan
Reported as:
Number · proportion of agreed cases
Inter-Reader Agreement
proportion of agreed casesAll Cases Read
Reader 1 v Reader 20.79
Reader 1 v Reader 30.79
Reader 1 v Reader 40.79
Reader 1 v Reader 50.81
Reader 2 v Reader 30.96
Reader 2 v Reader 40.88
Reader 2 v Reader 50.65
Reader 3 v Reader 40.92
Reader 3 v Reader 50.68
Reader 4 v Reader 50.72
Statistical analysis
  • All Cases Read · Fleiss' kappa: 0.80 · 95% CI 0.74 to 0.86
Other pre-specifiedDiagnostic Performance of Individual Readers (NFT Score B2-B3 as Truth Positive)

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. For this analysis, B scores of B2-B3 were considered truth positive, and B scores of B0-B1 were considered truth negative.

Time frame:
at autopsy within 9 months of baseline scan
Reported as:
Number · percentage of cases correctly identified
Diagnostic Performance of Individual Readers (NFT Score B2-B3 as Truth Positive)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs Autopsy NFT Score B2-B3Specificity of Flortaucipir vs Autopsy NFT Score B0-B1
Reader 180.4 (68.2 to 88.7)87.5 (52.9 to 97.8)
Reader 267.9 (54.8 to 78.6)100.0 (67.6 to 100.0)
Reader 367.9 (54.8 to 78.6)87.5 (52.9 to 97.8)
Reader 473.2 (60.4 to 83.0)87.5 (52.9 to 97.8)
Reader 585.7 (74.3 to 92.6)62.5 (30.6 to 86.3)

Adverse events

Collected over 9 months after flortaucipir scan, up to a total of 18 months if a subject was re-scanned per protocol. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Analysis Population73/156 (46.8%)3/156 (1.9%)14/156 (9%)
Most frequent serious events
Most frequent serious events
EventSafety Analysis Population
acute kidney injuryRenal and urinary disorders1/156
malignant neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/156
myocardial infarctionCardiac disorders1/156
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSafety Analysis Population
agitationPsychiatric disorders3/156
headacheNervous system disorders2/156
myocardial infarctionCardiac disorders1/156
vertigoEar and labyrinth disorders1/156
diarrhoeaGastrointestinal disorders1/156
nauseaGastrointestinal disorders1/156
injection site bruisingGeneral disorders1/156
fallInjury, poisoning and procedural complications1/156
procedural vomitingInjury, poisoning and procedural complications1/156
hypomagnesaemiaMetabolism and nutrition disorders1/156

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled Cohort
Mean80.2 ± 12.51
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Cohort
Female86
Male70
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Enrolled Cohort
Hispanic or Latino20
Not Hispanic or Latino136
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Enrolled Cohort
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American11
White143
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Enrolled Cohort
United States151
Australia5
08

Study locations

31 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Cherlin Research
    Los Gatos, California 95032, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
  • California Research Foundation
    San Diego, California 92103, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Ray Dolby Brain Health Center
    San Francisco, California 94114, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Neuropsychiatric Research Center of Southwest Florida
    Fort Myers, Florida 33912, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Merritt Island Medical Research
    Merritt Island, Florida 32952, United States
  • Miami Jewish Health Systems
    Miami, Florida 33137, United States
  • D de la Vega MD Research Group
    Miami, Florida 33185, United States
  • Bioclinica
    Orlando, Florida 32806, United States
  • Emory University Brain Health Center
    Atlanta, Georgia 30329, United States
  • Alzheimer's Disease Center
    Quincy, Massachusetts 02169, United States
  • Steinberg Diagnostics
    Henderson, Nevada 89052, United States
  • Adirondack Medical Research Center
    Glens Falls, New York 12801, United States
  • Clarity Clinical Research, LLC
    Syracuse, New York 13210, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Valley Medical Primary Care
    Centerville, Ohio 45459, United States
  • Hospice of the Western Reserve
    Cleveland, Ohio 44119, United States
  • American Clinical Trials, LLC (Site 1216)
    Oklahoma City, Oklahoma 73112, United States
  • Oklahoma Behavioral Health
    Oklahoma City, Oklahoma 73112, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Sante Clinical Research
    Kerrville, Texas 78028, United States
  • Overlake Internal Medicine Associates, PS
    Bellevue, Washington 98004, United States
  • University of Washington Medicine
    Seattle, Washington 98104, United States
  • University of Melbourne
    Parkville, Victoria 3010, Australia
09

References and documents

Publications

  • Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007. PubMed 22265587 ↗
  • Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012 Jan;123(1):1-11. doi: 10.1007/s00401-011-0910-3. Epub 2011 Nov 20. PubMed 22101365 ↗
  • Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, Salloway S, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonomovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Southekal S, Mintun MA; A16 Study Investigators. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020 Jul 1;77(7):829-839. doi: 10.1001/jamaneurol.2020.0528. Erratum In: JAMA Neurol. 2023 Aug 1;80(8):873. doi: 10.1001/jamaneurol.2023.1911. PubMed 32338734 ↗
  • Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr, Navitsky M, Kennedy I, Joshi AD, Lu M, Serrano GE, Sue LI, Intorcia AJ, Rose SE, Wilson A, Hellstern L, Coleman N, Flitter M, Aldea P, Fleisher AS, Mintun MA, Siderowf A. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. EJNMMI Res. 2020 Jun 15;10(1):65. doi: 10.1186/s13550-020-00653-x. PubMed 32542468 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Jun 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 2 years 2 months after primary completion. A results delay was requested in Aug 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Aug 5, 2015
Start
Sep 2015
Primary completionActual
Jun 13, 2018
CompletionActual
Jul 15, 2018
Results delay requested
Aug 19, 2019
Results first posted
Sep 7, 2020
Last update
Sep 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02516046
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Sep 2015
Primary completion
Jun 13, 2018
Completion
Jul 15, 2018
Results posted
Sep 7, 2020
Last update
Sep 7, 2020

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion